Latest Licensing Agreements News

Dimerix has received a US$10 million upfront payment from Everest Medicines under a regional licensing deal for DMX-200 targeting FSGS in Greater China, South Korea and Southeast Asia. This deal marks Dimerix’s fifth commercial partnership for DMX-200, collectively worth up to A$1.9 billion in milestones and royalties.

Yowie Group's revenue declined in the first half of 2026 as it navigated supply chain shifts and cautious retail demand, but the company secured a significant Australian licensing deal and ended costly legacy litigation.

Audeara has reached a key milestone as its chip-level AI licensing partnership with Optek enters commercial production, receiving initial purchase orders worth about A$31,000. This validates Audeara’s scalable fee-per-chip licensing model and sets the stage for broader applications in audio and hearing health.

Dimerix Limited (ASX: DXB) has inked its fifth regional licensing agreement with Everest Medicines, boosting potential milestone payments to A$1.9 billion and expanded its kidney disease pipeline through the acquisition of DMX-652. The Phase 3 ACTION3 trial for DMX-200 remains statistically robust, with funding secured to advance both clinical programs.

Audeara Ltd posted record FY26 cash receipts of $4.2 million and unaudited revenue of $4.44 million, driven by progress in AI audio licensing, exclusive assistive listening deals, and a large-scale Auracast deployment across retirement villages.

Argent BioPharma has eliminated US$5.5 million in secured debt through a global licensing agreement for its CannEpil® epilepsy therapy, while completing a key acquisition and advancing clinical trials in veterinary therapeutics.

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.

FINEOS Corporation Holdings PLC reported a solid €39 million cash balance for Q2 2026 despite a 23% drop in client receipts due to timing. The company locked in a significant 10-year deal with OneAmerica Financial and maintained its FY26 revenue guidance between €147m and €152m.

Recce Pharmaceuticals secured a non-binding term sheet with a major Middle Eastern pharma for its diabetic foot infection treatment and raised A$4 million to fund pivotal Phase 3 trials in Australia and Indonesia.

Temas Resources has filed a new patent for extracting chromium using its Regenerative Chloride Leach technology, broadening its critical minerals platform and commercial prospects.

FirstWave Cloud Technology has secured a 12-month extension of its ISM-compliant CyberCision platform agreement with Telstra, increasing annual recurring revenue from Federal Government agencies by 5% to approximately A$0.6 million.

First Graphene has signed an MOU with Sixth Element to distribute its PureGRAPH® CEM additive across China, with potential for local manufacturing via a joint venture once sales milestones are met.